Proteon Therapeutics, Inc is a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with renal and vascular diseases. The company is leveraging a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics. Proteon Therapeutics’ first drug candidate (PRT-201) is in development for the improvement of blood flow following vascular surgery procedures. The Company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD).

Headlines

Proteon Therapeutics appoints Gregory D. Phelps, a seasoned biopharmaceutical executive, to the Company's Board of Directors.

Proteon Therapeutics, Inc., announced today that a key patent has been issued by the European Patent Office.

Proteon Therapeutics to Present at Annual Meeting of American Society of Nephrology in San Francisco on November 2, 2007

Proteon Therapeutics completes $12 million financing and hires CFO

Proteon Therapeutics receives second issued U.S. patent broadly covering elastase vasodilation

Proteon Therapeutics adds experienced research and drug development talent to its team

EDC of Kansas City announces creation of “Kansas City Biotechnology Center”

Proteon Therapeutics receives issued U.S. patent broadly covering new method of artery and vein dilation

Proteon Therapeutics selects QSV Biologicals, Ltd for PRT-201 manufacturing

Proteon Therapeutics hires veteran biotechnology executive as CEO

Proteon Therapeutics, Inc. closes $19M in Series A financing